



AcouSort expands and moves to new, larger premises

Since June 2017, AcouSort has conducted its operations from the same premises at Medicon Village in Lund. As the company's operations have expanded, the premises have become too small. AcouSort will therefore on April 1 move into new larger and more appropriate premises at Medicon Village.

AcouSort is expanding its operations and moving to new, larger and more efficient premises on April 1. The new premises are as the previous located at Medicon Village in Lund.

In February this year, AcouSort expanded its team for customer Application Development & Support. This team is the one conducting the Company's technical interactions with current and potential customers. AcouSort will also soon expand to strengthen the development of the company's production capability.

– AcouSort has now reached the stage where the commercialization of our products is beginning to gain momentum. At the same time, research and development continue to grow. It is very positive that we have grown out of our suit and are moving to larger premises accommodating better the phase we are in now, says AcouSort's CEO Torsten Freltoft.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.